Targeting Eph receptors with peptides and small molecules: progress and challenges. - Wikidata - awgldk - TriplyDB

Targeting Eph receptors with peptides and small molecules: progress and challenges.

Targeting Eph receptors with peptides and small molecules: progress and challenges.

http://www.wikidata.org/entity/Q37951723

about

Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation Discovery of a Novel Chemotype of Tyrosine Kinase Inhibitors by Fragment-Based Docking and Molecular Dynamics Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation Vascular endothelial growth factor (VEGF) and platelet (PF-4) factor 4 inputs modulate human microvascular endothelial signaling in a three-dimensional matrix migration context.Comparative transcriptomic analysis of multiple cardiovascular fates from embryonic stem cells predicts novel regulators in human cardiogenesis.Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4 Identification and characterization of Nanobodies targeting the EphA4 receptor.Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols.Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.Eph receptor tyrosine kinases in cancer stem cells Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.Distinctive Structure of the EphA3/Ephrin-A5 Complex Reveals a Dual Mode of Eph Receptor Interaction for Ephrin-A5.Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.Investigation of the interactions between the EphB2 receptor and SNEW peptide variants.Targeted delivery of paclitaxel to EphA2-expressing cancer cells Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor.Eph receptor signaling and ephrins Tie2 and Eph receptor tyrosine kinase activation and signaling.Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.The role of EPH receptors in cancer-related epithelial-mesenchymal transition The role of ephrins' receptors and ephrins' ligands in normal placental development and disease.Eph receptors and ephrins: therapeutic opportunities.Inhibiting Eph kinase activity may not be "Eph"ective for cancer treatment.Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer.Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.An efficient bioorthogonal strategy using CuAAC click chemistry for radiofluorinations of SNEW peptides and the role of copper depletion.EPHB4 Mutation Implicated in Capillary Malformation-Arteriovenous Malformation Syndrome: A Case Report.Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs.The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures

P2860

Q27014166-4932AC3A-1725-4099-816F-BA3CFFF97D15 Q27684119-37C235BC-C59C-4706-9D82-BF42EE72A268 Q28116202-9E647636-1C78-4E02-A877-D16557A399D1 Q30559386-8CD3F523-698E-4B47-A9AC-4048BE352638 Q30651353-DDCA8894-4F6C-41EC-8079-9293456ADA00 Q33618844-55CDC10E-658A-49A5-BECD-F79D01E52C34 Q33882055-A384D21C-487D-4909-9C7F-044BD0DF5CCA Q34323180-F6141F84-AF10-42B4-A434-6A03CC2C4148 Q34414436-8F16F1F0-63F4-4CE4-87C6-67225DCACA10 Q34527304-74637C4A-CB71-4660-B288-0BCF8101FDE5 Q34756811-D1C30B08-176C-4E42-B3AD-A5003AC26B19 Q34953306-47B54C38-D8B9-4E82-BC3C-C5A11B4A2FE9 Q35636759-922AEF1F-A4F4-4EEF-8C92-5CF128F1D559 Q36040355-27BC7F35-25D4-4340-B132-82C57D6A4D77 Q36232264-901B38EA-80A5-42A2-8BCB-5D0B315B2A6C Q36511070-A483671F-649E-4316-BE57-AA0824768510 Q36914295-343B73C0-9466-4E40-B98E-A6736EFBDD5C Q37122330-A3F546A8-1702-46B0-95DE-E6400A0D84A4 Q37629840-27C81A68-603E-40A8-A041-00BB073FDA24 Q37635711-D1A888F9-4E35-4CC1-8821-480B14F07740 Q38150596-4AF632E1-A74F-48D1-9194-88D25BCC1F1B Q38170487-7B1B6F66-5540-4F67-9FA3-EFDF4F907216 Q38257853-CF761714-A745-45DB-8856-C00DD12F7751 Q38270107-4203F29B-0495-4511-81BE-DE9B42760C76 Q38702282-C3E9C3CE-B5C5-4FD9-9F50-5A414C44291A Q38951519-AB1E96E9-F403-478F-BBAB-D184E14ED2BF Q38990966-ED09F55A-D11C-42F6-B1DC-A9738002191F Q39017426-A549595C-3347-4C94-8A62-002DA7CC902A Q39072727-83ACE75A-8615-4D67-BE0B-D62BD9E10C2A Q39081789-99F26E83-D3B7-408C-A016-BEE7CED746CF Q39359728-9869F6C0-0D25-4972-8B40-3DE924B9CA5A Q39397346-9D0C5BCA-DDD5-4CBA-A077-11E85E4E505B Q41114856-226981BD-96F5-4206-94DB-61629B8BB470 Q41821364-1F0F9BFA-0CB8-4E9F-9160-2D9D4D2D76DE Q41867076-CB06B511-92F0-4B8B-AAF2-292A81F87AF6 Q41989875-E06BE055-14C0-4D04-8E40-B2CA8589FD23 Q44446237-F96792CA-C850-4A33-9645-8AB9C01A5965 Q48089344-5E143ACC-1964-4B69-9B80-EAB88D68F3E3 Q54111168-67171A74-DE52-47EF-AA39-B7E966F92514 Q57147941-FA1967B4-18AF-4415-B8CD-240394916D5A

P2860

Targeting Eph receptors with peptides and small molecules: progress and challenges.

http://www.wikidata.org/entity/Q37951723

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Targeting Eph receptors with peptides and small molecules: progress and challenges.

@en

Targeting Eph receptors with peptides and small molecules: progress and challenges.

@nl

type

label

Targeting Eph receptors with peptides and small molecules: progress and challenges.

@en

Targeting Eph receptors with peptides and small molecules: progress and challenges.

@nl

prefLabel

Targeting Eph receptors with peptides and small molecules: progress and challenges.

@en

Targeting Eph receptors with peptides and small molecules: progress and challenges.

@nl

P1433

Q37951723-DDD21BAA-0049-4C43-8D3C-DE86985FD3D2

P1476

Q37951723-B172FDAF-79E3-4CD3-8CEB-138CF09FF61D

P2093

Q37951723-01774BD6-13ED-4C03-A15A-591259121CD3

Q37951723-525AB563-328D-46CF-BDA3-6C3B95045154

Q37951723-B879D61E-3292-4E2F-9B0D-958FB6D7F160

P2860

Q37951723-019F03A7-388A-48C5-A71F-8DA33AB34998

Q37951723-05CDAC1F-F755-4BD2-9BA3-9E1CEF058C28

Q37951723-0D9F3F5B-51C8-46BB-B3F0-DE94399327CB

Q37951723-246E8F80-4F5E-4F13-84D5-CDF8262B9869

Q37951723-26E5D17B-101B-4485-A7B6-67FC06DE9C73

Q37951723-2764CC9A-78A5-4D44-A561-376EA2AB5FBE

Q37951723-28B223C6-E700-48C2-864E-B4ED2D7BD914

Q37951723-2B2B781D-88DF-48B9-84FE-E507401B3D65

Q37951723-2EF4F61A-2147-485E-B57E-0F48B2DB3CF5

Q37951723-3878FAE8-1302-4AB0-81E3-5AEB8EC93D2F

P304

Q37951723-258F4A9B-E123-4941-8313-56BAF2A1BA07

P31

Q37951723-34C6105A-2B51-46FF-B7B3-0189F35F1665

P356

Q37951723-59AD681B-29BE-4410-902B-90EC9924E369

P433

Q37951723-2864C4F1-6DC9-44B4-A3C2-976CDF5C8EA0

P478

Q37951723-6FD69530-277D-4804-9FDB-82D297F6727A

P577

Q37951723-707E8093-74EA-4947-8CFC-58D3790E0DE0

P5875

Q37951723-EF134B25-5DD5-441F-9064-2A2BC2F39D0D

P698

Q37951723-CFE7132A-59A3-4CBD-9866-6881F1482FA4

P932

Q37951723-6BE5EC1D-340B-419C-B42C-5183529140D7

P356

J.SEMCDB.2011.10.023

P1433

Seminars in Cell & Developmental Biology

P1476

Targeting Eph receptors with peptides and small molecules: progress and challenges.

@en

P2093

Elena B Pasquale

http://www.w3.org/2001/XMLSchema#string

Ilaria Lamberto

http://www.w3.org/2001/XMLSchema#string

Roberta Noberini

http://www.w3.org/2001/XMLSchema#string

P2860

Reversing EphB2 depletion rescues cognitive functions in Alzheimer model

The selectivity of protein kinase inhibitors: a further update

Three-dimensional Structure of the EphB2 Receptor in Complex with an Antagonistic Peptide Reveals a Novel Mode of Inhibition

Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines

Crystal Structure and NMR Binding Reveal That Two Small Molecule Antagonists Target the High Affinity Ephrin-binding Channel of the EphA4 Receptor

Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors

Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series

Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport.

A quantitative analysis of kinase inhibitor selectivity

Ephrins and Eph receptors in stem cells and cancer

P304

51-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SEMCDB.2011.10.023

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51762624

http://www.w3.org/2001/XMLSchema#string

P698

22044885

http://www.w3.org/2001/XMLSchema#string

P932

3319464

http://www.w3.org/2001/XMLSchema#string